Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02948283 · ClinicalTrials.gov registry record · Phase 1
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02948283 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 3 participants.
The verdict
NCT02948283, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the side effects and best dose of metformin hydrochloride and ritonavir in treating patients with multiple myeloma or chronic lymphocytic leukemia that has returned after a period of improvement or has not responded to treatment. Metformin hydrochloride and ritonavir may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Metformin Hydrochloride
- DRUG Ritonavir
- OTHER Pharmacological Study
- OTHER Quality-of-Life
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-09-05 |
| Est. Completion | 2017-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02948283
The ClinicalTrials.gov registry entry for NCT02948283 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02948283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02948283 about?
NCT02948283 is a clinical study titled "Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia". This pilot clinical trial studies the side effects and best dose of metformin hydrochloride and ritonavir in treating patients with multiple myeloma or chronic lymphocytic leukemia that has returned after a period of improvement or has not responded to treatment. Metformin hydrochloride and ritonavi...
What is the current status of trial NCT02948283?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-09-05. Estimated completion is 2017-12-01.
What interventions are being tested in trial NCT02948283?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Metformin Hydrochloride (DRUG), Ritonavir (DRUG), Pharmacological Study (OTHER), Quality-of-Life (OTHER).
Who is sponsoring clinical trial NCT02948283?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.